Prospective Randomized Trial of Early Postoperative Intraperitoneal Chemotherapy as an Adjuvant to Resectable Gastric Cancer
- 1 September 1998
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 228 (3), 347-354
- https://doi.org/10.1097/00000658-199809000-00007
Abstract
Surgeons have postulated on numerous occasions that cancer resection may participate in the dissemination of a malignancy. This randomized trial sought to determine whether a large volume of chemotherapy solution used perioperatively to flood the peritoneal cavity could eliminate microscopic residual disease and thereby improve survival of patients with gastric cancer. Surgical treatment failures in patients with gastric cancer are confined to the abdomen in most patients. Resection site and peritoneal surface spread, along with liver metastases, are the most common areas of recurrence. Survival and quality of life of patients with gastric cancer would be improved if disease progression at these anatomic sites was reduced. In a prospective randomized trial of 248 patients, intraperitoneal mitomycin C on day 1 and intraperitoneal 5-fluorouracil on days 2 through 5 were administered after gastric cancer resection. Patients who were thought to have stage II or stage III disease were randomized after resection to surgery alone versus surgery plus early postoperative intraperitoneal chemotherapy. After final pathologic examinations, there were 39 patients with stage I, 50 with stage II, 95 with stage III, and 64 with resected stage IV cancer. The 5-year survival of the surgery-only group was 29.3%, and the surgery-plus-intraperitoneal chemotherapy group was 38.7% (p = 0.219). In a subset analysis, the patients with stage I, stage II, and stage IV disease showed no statistically significant difference in survival. The 5-year survival rate of patients with stage III disease who underwent surgery only was 18.4% versus a survival rate of 49.1% for patients who underwent surgery plus intraperitoneal chemotherapy (p = 0.011). In a subset analysis, patients with stage III gastric cancer have shown a statistically significant improvement in survival when treated with perioperative intraperitoneal chemotherapy. Further studies in patients with gastric cancer with surgically directed chemotherapy are suggested.Keywords
This publication has 34 references indexed in Scilit:
- The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-upThe Lancet, 1994
- Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled studyCancer, 1994
- Cancer of the StomachAnnals of Surgery, 1993
- Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970British Journal of Surgery, 1992
- Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancerThe Lancet, 1992
- Does extensive dissection of lymph nodes improve the results of surgical treatment of gastric cancer?The American Journal of Surgery, 1990
- Gastrointestinal malignancy: Rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapyBritish Journal of Surgery, 1989
- Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin CCancer, 1988
- Cancer Of The ColonAnnals of Surgery, 1967
- Dissemination of Cancer with Special Emphasis on Vascular Spread and ImplantationAnnals of Surgery, 1965